Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines

Cell Proliferation

Volumn 40, Issue 4, 2007, Pages 580-594

  Rusnak, D W ^a   Alligood, K J ^a   Mullin, R J ^a,b   Spehar, G M ^a,c   Arenas Elliott, C ^a   Martin, A M ^a   Degenhardt, Y ^a   Rudolph, S K ^a   Haws Jr , T F ^a   Hudson Curtis, B L ^a   Gilmer, T M ^a  

^a GLAXOSMITHKLINE   (United States)

^b Piedmont Research Center   (United States)

^c Adherex Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG SELECTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; MALIGNANT TRANSFORMATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; HUMANS; MODELS, STATISTICAL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 34447310595     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2007.00455.x     Document Type: Article

References (20)

1. Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23, 5305 5313.
2. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R (2005) FDA drug approval summary: erlotinib (Tarceva®) tablets. Oncologist 10, 461 466.
3. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn Jr WD, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R (2004) United States Food and Drug Administration Drug Approval Summary Gefitinib (ZD1839; Iressa) Tablets. Clin. Cancer Res. 10, 1212 1218.
4. Fabian MA, Biggs III WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lelias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329 336.
5. Fakhry C, Gillison M (2006) Clinical implications of human papillomavirus in head and neck cancers. J. Clin. Onc. 24, 2606 2611.
6. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2783 2785.
7. Gillison ML, Glisson BS, O'Leary E, Murphy BA, Levine MA, Kies MS, Chan D, Forastiere AA (2006) ASCO Annual Meeting Proceedings Part I, Abstract 5511. J. Clin. Oncol. 24, 18S.
8. Harris RA, Eichholtz TJ, Hiles ID, Page MJ, O'Hare MJ (1999) New model of ErbB-2 over-expression in human mammary luminal epithelial cells. Int. J. Cancer 80, 477 484.
9. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630 1639.
10. Lu Y, Lin YZ, Lapushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB (1999) The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18, 7034 7045.
11. Mager ME (1972) Data Analysis in Biochemistry and Biophysics. New York: Academic Press.
12. Mosesson Y, Yarden Y (2004) Oncogenic growth factor receptors: implications for signal transduction therapy. Semin. Cancer Biol. 14, 262 270.
13. Neter J, Wasserman W, Kutner MH (1990) Applied Linear Statistical Models. Homewood, IL: Irwin.
14. Pegram MD, Pauletti G, Slamon DJ (1998) HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52, 65 77.
15. Petrov KG, Zhang YM, Carter M, Cockerill GS, Dickerson S, Gauthier CA, Guo Y, Mook Jr RA, Rusnak DW, Walker AL, Wood ER, Lackey KE (2006) Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorg. Med. Chem. Lett. 16, 4686 4691.
16. Ravaud G, Gardner J, Hawkins R, Von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Machiels J, El-Hariry I (2006) Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J. Clin. Oncol. Suppl. 24, 217s.
17. Rusnak DW, Lackey K, Wood ER, Alligood KJ, Rhodes N, Knight WB, Gilmer TM (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1, 85 94.
18. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ (2001) First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61 (Suppl. 2 37 42.
19. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652 6659.
20. Yeon CH, Pegram MD (2005) Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest. New Drugs 23, 391 409.